Literature DB >> 19443424

Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression.

Sabrina Tafuro1, Eduard Ayuso, Serena Zacchigna, Lorena Zentilin, Silvia Moimas, Franca Dore, Mauro Giacca.   

Abstract

AIMS: Members of the vascular endothelial growth factor (VEGF) family are among the most promising cytokines to induce neovascularization of ischaemic tissues; however, their unregulated expression often results in major undesired effects. Here, we describe the properties of inducible vectors based on the adeno-associated virus (AAV), allowing precise control of VEGF expression, and exploit these vectors to define the kinetics of the angiogenic response elicited by the factor. METHODS AND
RESULTS: Based on a tetracycline-inducible transactivator, we designed an AAV vector system allowing the pharmacological regulation of VEGF production in vivo and tested its efficacy in inducing functional neoangiogenesis in both normoperfused and ischaemic skeletal muscle in mice by a combination of histological, immunofluorescent, and molecular imaging techniques. We observed that a prolonged expression of VEGF was required to determine the formation of stable vessels, able to persist upon withdrawal of the angiogenic stimulus. However, the vessels formed in the presence of continuous VEGF expression consisted mainly of dilated and leaky capillaries. As determined after pinhole scintigraphy, this abnormal vasculature accounted for a significant drop in functional tissue perfusion. In contrast, transient VEGF expression, followed by a period of VEGF withdrawal, allowed maintenance of functional perfusion under resting conditions and during exercise. This VEGF-inducible system was highly effective in improving vascularization and function in a hind-limb ischaemia model.
CONCLUSION: Together, these results clearly indicate that the fine tuning of VEGF expression is required to achieve the formation of a stable vasculature able to sustain functional neovascularization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443424     DOI: 10.1093/cvr/cvp152

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  24 in total

1.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

2.  Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction.

Authors:  Lior Zangi; Kathy O Lui; Alexander von Gise; Qing Ma; Wataru Ebina; Leon M Ptaszek; Daniela Später; Huansheng Xu; Mohammadsharif Tabebordbar; Rostic Gorbatov; Brena Sena; Matthias Nahrendorf; David M Briscoe; Ronald A Li; Amy J Wagers; Derrick J Rossi; William T Pu; Kenneth R Chien
Journal:  Nat Biotechnol       Date:  2013-09-08       Impact factor: 54.908

3.  State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association.

Authors:  Michael Simons; Kari Alitalo; Brian H Annex; Hellmut G Augustin; Craig Beam; Bradford C Berk; Tatiana Byzova; Peter Carmeliet; William Chilian; John P Cooke; George E Davis; Anne Eichmann; M Luisa Iruela-Arispe; Eli Keshet; Albert J Sinusas; Christiana Ruhrberg; Y Joseph Woo; Stefanie Dimmeler
Journal:  Circ Res       Date:  2015-04-30       Impact factor: 17.367

4.  Enhanced athletic performance on multisite AAV-IGF1 gene transfer coincides with massive modification of the muscle proteome.

Authors:  Antero Macedo; Manuela Moriggi; Michele Vasso; Sara De Palma; Mauro Sturnega; Giorgio Friso; Cecilia Gelfi; Mauro Giacca; Serena Zacchigna
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

5.  Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164.

Authors:  Veronica Sacchi; Rainer Mittermayr; Joachim Hartinger; Mikaël M Martino; Kristen M Lorentz; Susanne Wolbank; Anna Hofmann; Remo A Largo; Jeffrey S Marschall; Elena Groppa; Roberto Gianni-Barrera; Martin Ehrbar; Jeffrey A Hubbell; Heinz Redl; Andrea Banfi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 6.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

7.  Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels.

Authors:  Ludovic F Melly; Anna Marsano; Aurelien Frobert; Stefano Boccardo; Uta Helmrich; Michael Heberer; Friedrich S Eckstein; Thierry P Carrel; Marie-Noëlle Giraud; Hendrik T Tevaearai; Andrea Banfi
Journal:  Hum Gene Ther Methods       Date:  2012-10       Impact factor: 2.396

Review 8.  Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.

Authors:  Gabor M Rubanyi
Journal:  Mol Ther       Date:  2013-02-12       Impact factor: 11.454

Review 9.  Therapeutic angiogenesis: controlled delivery of angiogenic factors.

Authors:  Hunghao Chu; Yadong Wang
Journal:  Ther Deliv       Date:  2012-06

10.  PGC-1α induces SPP1 to activate macrophages and orchestrate functional angiogenesis in skeletal muscle.

Authors:  Glenn C Rowe; Srilatha Raghuram; Cholsoon Jang; Janice A Nagy; Ian S Patten; Amrita Goyal; Mun Chun Chan; Laura X Liu; Aihua Jiang; Katherine C Spokes; David Beeler; Harold Dvorak; William C Aird; Zolt Arany
Journal:  Circ Res       Date:  2014-07-09       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.